Andreas S Beutler

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi Carbamazepine is an inhibitor of histone deacetylases
    Andreas S Beutler
    Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    Life Sci 76:3107-15. 2005
  2. ncbi Intrathecal gene transfer by adeno-associated virus for pain
    Andreas S Beutler
    Mount Sinai School of Medicine, Department of Medicine, Division of Hematology Oncology, New York, NY 10029, USA
    Curr Opin Mol Ther 7:431-9. 2005
  3. ncbi Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain
    Benjamin Storek
    Department of Medicine and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 105:1055-60. 2008
  4. ncbi The ZNF217 oncogene is a candidate organizer of repressive histone modifiers
    Michaela S Banck
    Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Epigenetics 4:100-6. 2009
  5. ncbi Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats
    Benjamin Storek
    Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Mol Pain 2:4. 2006
  6. ncbi Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma
    Jonathan D Schwartz
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Anticancer Drugs 15:439-52. 2004
  7. ncbi KLF6 degradation after apoptotic DNA damage
    Michaela S Banck
    Department of Medicine, Division of Hematology Oncology, P O Box 1079, Mount Sinai School of Medicine, One Gustave Levy Place, Room 24 42A, New York, NY 10029, USA
    FEBS Lett 580:6981-6. 2006

Research Grants

  1. Intrathecal Gene Transfer for Chronic Cancer Pain
    ANDREAS BEUTLER; Fiscal Year: 2007

Detail Information

Publications7

  1. ncbi Carbamazepine is an inhibitor of histone deacetylases
    Andreas S Beutler
    Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    Life Sci 76:3107-15. 2005
    ..These observations raise the possibility that HDAC inhibition may contribute to the pharmacological profile of CBZ...
  2. ncbi Intrathecal gene transfer by adeno-associated virus for pain
    Andreas S Beutler
    Mount Sinai School of Medicine, Department of Medicine, Division of Hematology Oncology, New York, NY 10029, USA
    Curr Opin Mol Ther 7:431-9. 2005
    ..AAV vectors may therefore become an important tool for translational studies to validate newly identified therapeutic targets in clinical pain states...
  3. ncbi Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain
    Benjamin Storek
    Department of Medicine and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 105:1055-60. 2008
    ..Therefore, gene transfer by LP may be suitable for developing gene therapy-based treatments for chronic pain...
  4. ncbi The ZNF217 oncogene is a candidate organizer of repressive histone modifiers
    Michaela S Banck
    Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Epigenetics 4:100-6. 2009
    ..Taken together, these findings suggest that ZNF217 assembles a distinct set of histone modifying proteins at target DNA sites that act synergistically in transcriptional repression...
  5. ncbi Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats
    Benjamin Storek
    Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Mol Pain 2:4. 2006
    ..Our studies focused on recombinant adeno-associated virus (rAAV), one of the most promising vector types for clinical use...
  6. ncbi Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma
    Jonathan D Schwartz
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Anticancer Drugs 15:439-52. 2004
    ..More adequately powered, rigorously conducted studies will hopefully identify useful chemo-, radio-, immuno-, embolization-based and biologically targeted therapies during the next decade...
  7. ncbi KLF6 degradation after apoptotic DNA damage
    Michaela S Banck
    Department of Medicine, Division of Hematology Oncology, P O Box 1079, Mount Sinai School of Medicine, One Gustave Levy Place, Room 24 42A, New York, NY 10029, USA
    FEBS Lett 580:6981-6. 2006
    ..KLF6 was unchanged by apoptosis via the extrinsic/death-receptor pathway. Deregulation of KLF6 stability may alter its tumor suppressor function and/or the response of tumors to chemotherapeutics...

Research Grants2

  1. Intrathecal Gene Transfer for Chronic Cancer Pain
    ANDREAS BEUTLER; Fiscal Year: 2007
    ....